Richard Laura, Ph.D.

Richard Laura, Ph.D. has held various positions in the pharmaceutical and biotechnology industry since 1999. Richard began their career as a Postdoctorate at Genentech, Inc. where they studied epithelial cell biology. From 2002 to 2010 they worked at Neurocrine Biosciences as a Senior Scientist, leading the protein biochemistry group and conducting studies on members of the class-B g-protein coupled receptor family. From 2010 to 2017 they were a Senior Research Scientist at Bolt Biotherapeutics, Inc., where they were the group leader for production, purification and characterization of immuno-modulatory ADC's, and developed methodologies to assess the in vivo stability and clearance rate of ADC's by mass spectrometry. Since 2020, they have been a Principal Scientist at Lycia Therapeutics.

Richard Laura, Ph.D. began their educational journey in 1987 when they attended the University of California, Davis, where they earned their Bachelor of Science in Biochemistry in 1992. Richard then went on to the University of Washington, where they completed their Ph.D. in Biochemistry in 1998.